Review for 10.1186/s12876-017-0582-0 (2017)

Reviewe r’s report  
 
Title: Comparison of telbivudine and entecavir on  the change of off - treatment eGFR after 3 
years of treatment in non -cirrhotic chronic hepatitis B patients  
 
Version: 0 Date: 12 Jun 2016  
 
Reviewer: King -Wah Chiu  
 
Reviewer's report:  
 
A retrospective study for the benefit effect on the GFR with 3 -year antiviral treatment for A 
retrospective study for the benefit effect on the GFR with 3 -year antiviral treatment for hepatitis 
B between LDT and ETV.   
Major comments:  
1. The major comment is focus on the conclusion section. This paragraph is too long in 
statement. The topic is emphasized a 3 -year study, the result of 4 -year should not be the 
comment on the conclusion.  
2. The English modification should be revise before a fi nal decision.  
 
Minor comments:  
1. The number of enrolled patients is not corrected on the flow chart (89 plus 91 is not equal to 
190) 
2. Tape error on the last line of page 13 the result section. (one form need to revise as from)  
3. Tape error on the list of last reference with the year 201?  
Are the methods appropriate and well described?  
If not, please specify what is requi red in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Not suitable for publication unless extensively edited  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain or lose financially from the publi cation of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you curr ently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any  other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests.  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is accepted for publication, my named rep ort 
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understa nd that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal